ALX-804-818-C100
antibody from Enzo Life Sciences
Targeting: NLRP3
AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1, DFNA34, FCAS, FCU, MWS, NALP3, PYPAF1
Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-804-818-C100 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-804-818-C100, RRID:AB_2051971
- Product name
- NLRP3/NALP3 (human) monoclonal antibody (Nalpy3-a)
- Antibody type
- Monoclonal
- Antigen
- Recombinant protein fragment
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- Nalpy3-a
- Vial size
- 100 μg
- Storage
- -20°C
- Handling
- Avoid freeze/thaw cycles.
Submitted references Reconstituted AIM2 inflammasome in cell-free system.
NLRP3 Deficiency Improves Angiotensin II-Induced Hypertension But Not Fetal Growth Restriction During Pregnancy.
Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases.
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder.
Kaneko N, Ito Y, Iwasaki T, Takeda H, Sawasaki T, Migita K, Agematsu K, Kawakami A, Morikawa S, Mokuda S, Kurata M, Masumoto J
Journal of immunological methods 2015 Nov;426:76-81
Journal of immunological methods 2015 Nov;426:76-81
NLRP3 Deficiency Improves Angiotensin II-Induced Hypertension But Not Fetal Growth Restriction During Pregnancy.
Shirasuna K, Karasawa T, Usui F, Kobayashi M, Komada T, Kimura H, Kawashima A, Ohkuchi A, Taniguchi S, Takahashi M
Endocrinology 2015 Nov;156(11):4281-92
Endocrinology 2015 Nov;156(11):4281-92
Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases.
Shio MT, Eisenbarth SC, Savaria M, Vinet AF, Bellemare MJ, Harder KW, Sutterwala FS, Bohle DS, Descoteaux A, Flavell RA, Olivier M
PLoS pathogens 2009 Aug;5(8):e1000559
PLoS pathogens 2009 Aug;5(8):e1000559
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder.
Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J
Immunity 2004 Mar;20(3):319-25
Immunity 2004 Mar;20(3):319-25
No comments: Submit comment
Supportive validation
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Immunofluorescence microscopy showing the detection of endogenous NLRP3/NALP3 in THP1 cellsÊusing NLRP3/NALP3 (human), mAb (Nalpy3-a) (Prod. No. ALX-804-818). Method: Following fixation with paraformaldehyde 3.7%, THP1 cells were incubated with NLRP3/NALP3 (human), mAb (Nalpy3-a) (Prod. No. ALX-804-818) at a 1:100 dilution. An anti-mouse IgG antibody conjugated with Alexa Fluor 488 was used for detection.